DXCM

DXCM

USD

DexCom Inc. Common Stock

$61.180+0.090 (0.147%)

实时价格

Healthcare
医疗设备
美国

价格图表

Loading Chart...

关键指标

市场指标
公司基本面
交易统计

市场指标

开盘价

$61.090

最高价

$62.390

最低价

$58.880

成交量

8.96M

公司基本面

市值

23.9B

所属行业

医疗设备

国家/地区

United States

交易统计

平均成交量

5.54M

交易所

NMS

货币

USD

52周价格范围

最低价 $56.45当前价 $61.180最高价 $93.25

AI分析报告

最后更新: 2025年11月4日
由AI生成数据来源: Yahoo Finance, Bloomberg, SEC

DXCM Analysis: DexCom's Rocky Road - Can Recent Bounce Hold?

Market Pulse Check

  • Current Price: $60.43 (as of 2025-11-03 close)
  • Recent Swing: +3.8% rebound after 61% decline since August highs
  • Key Technicals: MACD bearish crossover vs. surging 19x average volume

Price Action Breakdown

  • August-Sept Stability: Traded $75-$82 range
  • Sept 19 Crash: -11% drop on 3x average volume
  • October Freefall: 35% decline accelerated by legal news
  • November Lifeline: +3.8% gain on massive 17.8M shares traded

News Impact Matrix

SentimentCountKey Developments
Negative96 law firm investigations filed
Analyst Mixed128 lowered PTs (range $75-$99)
Positive1New board member appointment

AI Forecast Snapshot

TimeframePredictionNotes
1-day-0.8%Potential pullback after surge
2-day+1.6%Technical rebound potential
3-day+1.9%Resistance near $62 area

Strategic Considerations

For Active Traders:

  • Watch $61.15 breakout level (Nov 3 high)
  • Consider partial profits at $62.90 TP
  • Hard stop below $58.50 support

Long-term Investors:

  • Monitor lawsuit developments closely
  • Debt concerns (94% D/E ratio) require scrutiny
  • Potential accumulation zone if $58 holds

Bottom Line

DexCom's technical bounce faces fundamental headwinds. While AI models suggest near-term upside, the legal overhang creates exceptional risk. The stock needs to reclaim $62 decisively to suggest sustainable recovery. Healthcare sector exposure remains favorable, but DXCM requires tighter risk parameters than peers.


This analysis reflects market conditions as of November 4, 2025. Consider consulting a financial advisor before making investment decisions. Past performance doesn't guarantee future results. Data sources: Analyst reports, SEC filings, market data feeds.

相关新闻

PR Newswire

Stockholder Alert: Robbins LLP Informs Investors of the Dexcom, Inc. Class Action Lawsuit

Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Dexcom, Inc. (NASDAQ:...

查看更多
Stockholder Alert: Robbins LLP Informs Investors of the Dexcom, Inc. Class Action Lawsuit
Analyst Upgrades

UBS Maintains Buy on DexCom, Lowers Price Target to $95

UBS analyst Danielle Antalffy maintains DexCom with a Buy and lowers the price target from $106 to $95.

查看更多
UBS Maintains Buy on DexCom, Lowers Price Target to $95
Analyst Upgrades

Truist Securities Reiterates Buy on DexCom, Lowers Price Target to $82

Truist Securities analyst Richard Newitter reiterates DexCom with a Buy and lowers the price target from $94 to $82.

查看更多
Truist Securities Reiterates Buy on DexCom, Lowers Price Target to $82
Analyst Upgrades

Barclays Maintains Equal-Weight on DexCom, Lowers Price Target to $80

Barclays analyst Matt Miksic maintains DexCom with a Equal-Weight and lowers the price target from $98 to $80.

查看更多
Barclays Maintains Equal-Weight on DexCom, Lowers Price Target to $80
PR Newswire

DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against DexCom, Inc. ("DexCom" or...

查看更多
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm
PR Newswire

DXCM Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against DexCom, Inc. (DXCM) - Contact Kessler Topaz Meltzer & Check, LLP

The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against...

Analyst Upgrades

Wells Fargo Maintains Overweight on DexCom, Lowers Price Target to $93

Wells Fargo analyst Larry Biegelsen maintains DexCom with a Overweight and lowers the price target from $98 to $93.

AI预测Beta

AI建议

看涨

更新于: 2025年11月4日 21:09

看跌中性看涨

60.6% 置信度

风险与交易

风险等级3/5
中风险
适合于
激进保守增长
交易指南

入场点

$58.80

止盈点

$62.91

止损点

$52.39

关键因素

DMI显示看跌趋势(ADX:15.5,+DI:9.8,-DI:18.9),表明需谨慎
交易量是平均值的19.6倍(59,957),表明极强的买入压力
MACD -0.1446低于信号线-0.0199,表明看跌交叉

保持更新

设置价格提醒,获取AI分析更新和实时市场新闻。